Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Metastatic HER2 + breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. While first-line therapy is well-established for metastatic HER2 + breast cancer, the standard of care for second-line therapy will likely be changing soon based on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wynn, Carrie S., Tang, Shou-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924093/
https://www.ncbi.nlm.nih.gov/pubmed/35142964
http://dx.doi.org/10.1007/s10555-022-10021-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924093/
https://www.ncbi.nlm.nih.gov/pubmed/35142964
http://dx.doi.org/10.1007/s10555-022-10021-x

Ejemplares similares